Lavoltidine Information
Loxtidine (INN), also known as lavoltidine (USAN, BAN) or AH-23,844, is a highly potent and selective H2 receptor antagonist which was under development as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.[1][2]
Synthesis
See also
References
- ^ Washington, Neena (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN 0-8493-5444-7. http://books.google.com/books?id=MKxtXgtt5SIC&lpg=PA250&dq=loxtidine&pg=PA250#v=onepage&q&f=false.
- ^ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8. http://books.google.com/books?id=x2Su3GKCvtsC&lpg=PA4087&dq=lavoltidine&pg=PA4087#v=onepage&q&f=false.
- ^ Clitherow, J. W.; Bradshaw, J.; Price, B. J.; Martin-Smith, M.; Mackinon, J. W. M.; Judd, D. B.; Hayes, R.; Carey, L.; 1983, EP 0016565 .
|
||||||||||||||||||||||||||
Categories:
|